PFS of 63% after 5 years for patients with multiple myeloma in maintenance therapy with lenalidomide and dexamethasone

In this MEDtalk Laura Rosiñol, MD,Hematology Department, Hospital Clínic, Barcelona, Spain member of the PETHEMA-GEM, presents data for the potential benefit of postransplant maintenance therapy with Ixazomib/lenalidomide/dexamethasone as opposed to lenalidomide/dexamethasone alone.